Combining olaparib treatment with macrophage-targeting therapy by CSF1R-blocking antibodies significantly enhances the antitumour immune response and increases survival in mice with BRCA-deficient TNBC tumours [26]. This evidence concerns the gene CSF1R and neoplasm.